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This study aims at investigating the relationship between cyclooxygenase-2 expression in tumour vs stroma inﬂammatory
compartment and its possible clinical role. The study included 99 stage IB-IV cervical cancer patients: immunostaining of
tumour tissue sections was performed with rabbit antiserum against cyclooxygenase-2. CD3, CD4, CD8, CD25, Mast Cell
Tryptase monoclonal antibodies were used to characterise stroma inﬂammatory cells in nine cervical tumours. An inverse
relation was found between cyclooxygenase-2 levels (cyclooxygenase-2 IDV) of tumour vs stroma compartment (r=70.44,
P50.0001). The percentage of cases showing high tumour/stromal cyclooxygenase-2 IDV ratio was signiﬁcantly higher in
patients who did not respond to treatment (93.3%) with respect to patients with partial (60.5%), and complete (43.7%)
response (P= 0.009). Cases with a high tumour/stroma cyclooxygenase-2 IDV ratio had a shorter overall survival rate than
cases with a low tumour/stroma cyclooxygenase-2 IDV (P50.0001). In the multivariate analysis advanced stage and the status
of tumour/stroma cyclooxygenase-2 IDV ratio retained an independent negative prognostic role. The proportion of CD3
+,
CD4
+, and CD25
+ cells was signiﬁcantly lower in tumours with high tumour/stroma cyclooxygenase-2 IDV ratio, while a
higher percentage of mast cells was detected in tumours showing high tumour/stroma cyclooxygenase-2 IDV ratio. Our study
showed the usefulness of assessing cyclooxygenase-2 status both in tumour and stroma compartment in order to identify
cervical cancer patients endowed with a very poor chance of response to neoadjuvant therapy and unfavourable prognosis.
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Cyclooxygenase (COX), the key enzyme in the conversion of
arachidonic acid to prostaglandins, exists in two isoforms namely
COX-1, constitutively expressed in most tissues, and COX-2, which
is inducible by growth factors, prostaglandins, and tumour promo-
ters and associated with the inﬂammatory response (Williams and
Dubois, 1996). It has been reported that COX-2 overexpression is
associated with inhibition of apoptosis and host immune
responses, and increased metastatic potential and neoangiogenesis
(Tsujii and Dubois, 1995; Tsujii et al, 1998; Stolina et al, 2000).
In this context, it is not surprising that COX-2 has been associated
with parameters of tumour aggressiveness and unfavourable clinical
outcome in several solid tumours (Ferrandina et al, 2002a; Tomo-
zawa et al, 2000; Ristimaki et al, 2002). As far as cervical cancer is
concerned, recent reports showed that high COX-2 expression is
associated with diminished survival in cervical cancer patients
administered radiotherapy (Gaffney et al, 2001). We also recently
demonstrated that high COX-2 expression in tumour cells can
identify cervical cancer patients with a poor chance of response
to neoadjuvant chemotherapy and worse prognosis (Ferrandina et
al, 2002b).
There is some evidence that, besides the expression in tumour
cells, COX-2 is also expressed in stromal cellular elements such
as endothelial cells, macrophages, and ﬁbroblasts (Masferrer et al,
2000), stimulated T-lymphocytes and activated mast cells (Iniguez
et al, 1999; Hundley et al, 2001).
The potential role of COX-2 expression in stroma cells has been
ﬁrst suggested by Williams et al (2000), who showed a dramatic
inhibition of tumour growth and angiogenesis in lung carcinoma
cells grafted into homozygous COX-2
7/7 mice.
Based on our preliminary observations about the presence of
COX-2 staining in the stroma compartment of cervical tumours
we were then prompted at providing a more in depth analysis of
(i) COX-2 content in the stroma inﬂammatory cellular elements
of this neoplasia, (ii) the relationship between COX-2 expression
in tumour cells vs stroma inﬂammatory compartment, and (iii)
the possible clinical role of COX-2 expression according to the
cellular compartment of staining.
In addition, an immunophenotypic characterization of stroma
inﬂammatory cells was carried out in a series of cervical tumours.
PATIENTS AND METHODS
The study included 99 stage IB-IV cervical cancer patients consecu-
tively admitted to the Department of Obstetrics and Gynecology,
Division of Gynecologic Oncology, Catholic University of Rome
between November 1995 and September 2001. Median age was
51 years (range 24–76). The clinico-pathological characteristics
are summarised in Table 1. The clinical management of our patient
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www.bjcancer.compopulation was as previously described (Ferrandina et al, 2002b):
cases with early stage disease (FIGO Stage IB-IIA, major tumour
diameter less than 4 cm) were primarily submitted to radical
surgery (n=24), whereas locally advanced cancer cases (n=75) were
ﬁrst administered neoadjuvant cisplatin-based treatment (cisplatin
dose 100 mg m
2 every 3 weeks for 2–3 courses). In case of clinical
response, assessed by the above described procedures and recorded
according to WHO response evaluation criteria (World Health
Organization, 1979), LACC patients were submitted to radical
surgery (n=61): operative technique consisted of type II–IV radical
hysterectomy, and systematic pelvic lymphadenectomy. An anterior
exenteration was performed in two cases with persisting involve-
ment of the bladder after neoadjuvant treatment. Para-aortic
lymphadenectomy up to the level of inferior mesenteric artery
was performed in high risk patients as previously reported (Bene-
detti-Panici et al, 1996). Patients showing clinical no change/
progression during neoadjuvant treatment were subjected to exclu-
sive radiotherapy.
Antibodies
The following monoclonal and policlonal antibodies were used:
anti-CD3 (clone PS1; 1:100), anti-CD4 (clone 1F6; 1:50), anti-
CD8 (clone 4B11; 1:50), anti-CD25 (clone 4C9; 1:100), all from
Ylem (Avezzano, Italy); anti-Mast Cell Tryptase (clone AA1,
1:100 (DAKO, Glostrup, Denmark); anti-COX 2 rabbit policlonal
antibody (1:300 Cayman, Ann Arbor, MI, USA).
Immunohistochemical studies
Tumour tissues biopsies were performed under colposcopic exam-
ination. Immunohistochemistry of COX-2 was performed as
previously described (Ferrandina et al, 2002b). In the studies of
phenotyping of stromal inﬂammatory cells, serial sections of repre-
sentative blocks were cut from patients with either high (41) or
low (41) COX-2 positive tumour/stroma ratio (see below). In
order to quantitate the percentage of COX-2 stained cell subpopu-
lations with respect to inﬂammatory cells of the stroma, we used
the immunoperoxidase technique performed on consecutive
sections, since it allows by nuclear counterstaining with hematox-
ylin to better recognise stromal cells also by their morphological
characteristics.
Negative controls were performed using non immunised rabbit
serum and/or omitting the primary antibodies. As positive controls
for COX-2 antibody, COX-2 positive Hep-2 squamous cancer cells
and COX-2 positive squamous cancer tissue specimens (Ranelletti
et al, 2001) were always run in the assay. As positive controls for
the other antibodies both lymph-nodes and thymus were used.
Double-labelling subtraction immunostaining
Double-labelling subtraction immunostaining was carried out as
previously reported (Yamada et al, 1998). Brieﬂy, after routine
immunostaining for COX-2, the slide was treated with 3-amino-9
ethylcarbazole (Sigma, St. Louis, MO, USA). The slide was rapidly
mounted using an aqueous mounting medium and digital images
of microscopic ﬁelds acquired by Nikon Coolpix 950 digital camera
(Nikon Instruments, Florence, Italy) after registering the X-Y coor-
dinate of the acquired ﬁeld in the slide. Then the slide was
immersed in Ca
2+-Mg
2+-free PBS (pH 7.2), and washed with
PBS. The slide was immersed for 10 s in 99.8% (vol/vol) methyl
alcohol and then exhaustively washed with PBS. The section was
treated in microwave owen using the Dako ChemMate detection
kit (DAKO) and then incubated with anti-mast cell tryptase anti-
body. The immunoreaction was developed by fast blue and the
slide was remounted. The exact area on the same slide was
acquired by the digital camera and compared with the ﬁrst image.
As a control, after the ﬁrst immunostaining with anti-COX-2 anti-
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Table 1 Distribution of tumour/storma COX-2 IDV ratio according to clinico-pathological character-
istics of cervical cancer population
High tumour/stroma Tumour/stroma
No. of COX-2 IDV ratio COX-2 IDV ratio
Characteristics patients no. (%) P value
a (mean+s.e.) P value
b
All cases 99 56 (56.6) 5.1+0.9
Age (years)
550 46 23 (50.0) 4.3+1.1
550 53 33 (62.3) 0.30 5.7+1.3 0.12
FIGO stage
IB 25 11 (44.0) 4.0+1.3
II 56 30 (55.6) 4.9+1.2
III-IV 18 15 (83.3) 0.029 7.0+2.3 0.09
Histotype
Squamous 81 41 (50.6) 3.9+0.8
Adenocarcinoma 12 12 (100) 12.9+4.4
Adenosquamous 6 3 (50) 0.052
c 5.6+2.5 0.0005
c
Grade
1–2 37 23 (62.0) 4.7+1.3
3 52 27 (51.9) 0.84 4.6+1.2 0.89
Not available 10 –
Tumour size (cm)
54 37 15 (40.5) 2.4+0.6
54 62 41 (66.1) 0.023 6.6+1.3 0.011
Clinical response
d
Complete 16 7 (43.7) 4.2+2.1
Partial 43 26 (60.5) 4.9+1.1
NC/P 16 15 (93.7) 0.009 10.6+3.6 0.032
aCalculated by w
2 test.
bCalculated by Kruskal-Wallis non parametric test.
cSquamous vs other histotypes.
dResults are
relative to LACC patients.
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Figure 1 (A) Squamous cervical cancer with intense COX-2 immunoreaction in both cytoplasm and nuclei of tumour cells. Scattered cells in the stromal
compartment are stained. (B) COX-2 negative tumour showing intense COX-2 staining in the stroma inﬂammatory compartment. CD3, CD4, CD25, and
tryptase immunoreaction in tumours showing high (C, E, G) vs low (D, F, H) tumour/stroma COX-2 IDV ratio. Bar=50 mm( A,B); Bar=25 mm( C–H).
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with the streptavidin-biotin-alkaline phosphatase complex kit,
omitting the anti-mast cell tryptase antibody.
Quantiﬁcation of immunohistochemical staining
The intensity of immunohistochemical staining was evaluated as
previously reported (Ranelletti et al, 2001) by the image analysis
based on Photoshop (Adobe System, San Jose, CA, USA) together
with ‘The image processing toolkit’ (CRC Press, Boca Raton, FL,
USA). The integrated density values (IDV) of the immunostaining
was calculated as the product of the mean density value of the
immunoreactive regions by the percentage of the immunostained
tumour or stroma components. Inﬂammatory cell count in the
tumour stroma was performed by chosing ﬁve corresponding
620 ﬁelds, from each of six serial tissue sections (one for each
antibody), so as to best reﬂect the overall immunostaining of the
tumour stroma contained in the entire slide. The ﬁles, acquired
with a Nikon Coolpix 950 digital camera, were opened in Photo-
shop using a Macintosh G3 workstation (Apple, Cupertino, CA,
USA). Both immunostained and negative cells within a superim-
posed grid of 0.022 mm
2 were counted. Two cell counts for each
digital image were done by moving the grid over representative
stromal areas. The total cell number/stromal area was calculated
by averaging cell counts from each section and from the six conse-
cutive sections (n=60). The number of immunostained cells,
relative to each phenotype, was calculated by averaging cell counts
from two grid areas from ﬁve 620 ﬁelds (n=10). The results were
reported as mean+s.e.
Statistical analysis
The w
2-test was used to analyse the distribution of COX-2 positive
cases according to several clinico-pathological features. Kruskal–
Wallis non parametric test was used to analyse the distribution
of tumour/stroma COX-2 integrated density values according to
clinico-pathological variables. Medians and life tables were
computed using the product-limit estimate by the Kaplan and
Meier method (Kaplan and Meyer, 1958) and the log-rank test
was employed to assess the statistical signiﬁcance (Mantel, 1966).
The prognostic role of COX-2 as a continuous variable, was also
analysed by means of the Cox proportional hazard model (Cox,
1972). A Cox’s regression model with stepwise variable selection
(Cox, 1972) and multiple logistic analysis (Cox, 1970) were used
to analyse the role of clinico-pathological parameters and COX-2
staining as prognostic factors and predictors of response to neo-
adjuvant treatment. Wald statistics for coefﬁcient comparison
and the Joint signiﬁcance test were also performed in order to
compare the coefﬁcients of relative risk of death for tumour
COX-2 positivity vs tumour/stroma COX-2 IDV ratio positivity
and to evaluate the weight of the status of tumour COX-2 and
tumour/stroma COX-2 IDV ratio in the survival regression model
after excluding each of them.
Statistical analysis was carried out using SOLO (BMDP Statisti-
cal Software, Los Angeles, CA, USA) and Statview survival tools
(Abacus Concepts- Inc- Berkeley CA, USA).
RESULTS
Cox-2 immunostaining
Figure 1A and B shows COX-2 immunoreaction in two primary
squamous cervical tumours. COX-2 immunostaining was observed
both in the tumour cells as well as in the stroma inﬂammatory
compartment of the tumour. Interestingly, in the presence of
strong COX-2 staining in tumour cells, only barely detectable
COX-2 immunoreaction was observed in the stroma inﬂammatory
compartment (Figure 1A). On the other hand, a large amount of
stroma inﬂammatory component showing positive COX-2 immu-
nostaining was frequently detected in association with low or
absent COX-2 staining in tumour cells (Figure 1B).
In the whole series, COX-2 integrated density values in the
tumour component ranged from 1.2 to 82.3 with mean+s.e. values
25.5+2.2. COX-2 integrated density values in the stromal compo-
nent range from 0.9 to 96.0 with mean+s.e. values of 20.0+1.9.
A statistically signiﬁcant inverse relation was found between
COX-2 IDV of tumour vs COX-2 IDV in the stroma compartment
(r=70.44, P50.0001) (data not shown).
For this reason, the ratio between COX-2 IDV in the tumour vs
COX-2 IDV in the stroma component was used in order to
normalise the COX-2 expression in each case, and to categorise
tumours according to low vs high COX-2 content. The tumour/
stroma COX-2 IDV ratio range from 0.03 to 48.2
(mean+s.e.=5.1+0.9). The ratio of 41 was used to indicate cervi-
cal tumours with COX-2 expression in the tumour component
lower or equivalent to COX-2 expression in the stroma.
According to the chosen cut off value, 56 out of 99 (56.6%)
were scored as having a high (41) tumour/stroma COX-2 IDV
ratio.
Correlation with clinico-pathological parameters
High COX-2 IDV in the tumour compartment were shown to be
signiﬁcantly associated with larger volume of the tumour and more
aggressive histotype while COX-2 IDV in the tumour stroma
showed the opposite pattern (data not shown).
The percentage of cases with high tumour/stroma COX-2 IDV
ratio increased from 44.0% in stage I, through 55.6% in stage II,
to 83.3% in stage III–IV cases (P value=0.029). Moreover, cases
with high tumour/stroma COX-2 IDV ratio were more frequently
observed in cases with tumour volume 54 cm than in smaller
tumours (66.1% vs 40.5%) (P value=0.023). No association with
age, and grade of differentiation was found (Table 1).
Similarly, higher tumour/stroma COX-2 IDV ratio was found in
stage III-IV with respect to stage I–II cases (P value=0.09), in
adenocarcinoma and adenosquamous carcinoma versus squamous
cell (P value=0.0005), in tumours 54c mvs smaller tumours (P
value=0.011).
Metastatic lymph node involvement was found in 14 out of 69
(20.3%) cases: the percentage of COX-2 tumour positivity was
28.6% in lymph node positive with respect to 35.7% in lymph
node negative cases (difference not signiﬁcant).
COX-2 status and response to neoadjuvant treatment
The percentage of cases showing tumour COX-2 positivity was
signiﬁcantly higher in patients who did not respond to treatment
(87.5%) with respect to patients with partial (46.5%), and
complete (31.2%) response (P=0.003). Similar results were found
considering COX-2 IDV ratio as covariate, according to clinical
response (P=0.007) (data not shown). On the other hand, the
percentage of cases showing COX-2 IDV positivity in the stroma
was not correlated per se with response to treatment (data not
shown).
The percentage of cases showing high tumour/stromal COX-2
IDV ratio was signiﬁcantly higher in patients who did not respond
to treatment (93.3%) with respect to patients with partial (60.5%),
and complete (43.7%) response (P=0.009). Similar results were
found considering mean COX-2 IDV ratio according to clinical
response (Table 1).
In the univariate analysis advanced FIGO stage, and high
tumour/stroma COX-2 IDV ratio proved to associated with poor
chance of response to neoadjuvant therapy (complete/partial vs
no response). When logistic regression was applied, FIGO stage
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2=7.0, P=0.008) and tumour/stroma COX-2 IDV ratio (w
2=4.1,
P=0.0042) retained an independent role in predicting a poor
chance of response to treatment.
Survival analysis
Follow up data were available for 99 patients. As of December
2001, the median follow up was 23 months (range=3–73 ).
During the follow up period, 21 out of 99 (21.2%) patients died
of disease. For analysis of survival COX-2 status in tumour cells
was deﬁned according to the cut-off used in our previous study
(Ferrandina et al, 2002b) and corresponding to the mean of
COX-IDV. Similarly, COX-2 status in stroma inﬂammatory cells
was deﬁned according to the cut-off of 20.0 corresponding to
mean COX-2 IDV.
Cases showing COX-2 positive reaction in tumour cells (Figure
2A) showed a shorter OS than COX-2 negative cases: in particular,
the 3-year OS was 53% (conﬁdence intervals 95% – CI 95% –
35–71) with respect to COX-2 negative cases who had a 3-year
OS of 87% (CI 95%=75–99) (P=0.0001). COX-2 IDV in tumour
cells were directly associated with risk of death, using COX-2
values as a continuous covariate (w
2=16.6, P=0.0001) (data not
shown).
On the other side, cases showing COX-2 positive reaction in
stroma inﬂammatory cells showed a longer OS than COX-2 nega-
tive cases: in particular, the 3-year OS was 91% (CI 95%=79–101)
in COX-2 positive with respect to COX-2 negative cases who had a
3-year OS of 59% (CI 95%=46–72) (P=0.010) (Figure 2B). COX-2
IDV in stroma inﬂammatory cells were inversely associated with
risk of death, as assessed by COX analysis using COX-2 values as
a continuous covariate (w
2=8.2, P=0.004) (data not shown).
Cases with a high tumour/stroma COX-2 IDV ratio had a short-
er OS than cases with a low tumour/stroma COX-2 IDV ratio: in
particular, all deaths of disease but one occurred in the former
group (P50.0001) (Figure 2C). Similar results were observed in
the subgroup of LACC patients (data not shown). The use of an
arbitrary cut-off to distinguish cases with high vs low tumour/stro-
ma COX-2 IDV ratio is unlikely to have introduced any bias, since
a direct association between tumour/stroma COX-2 IDV ratio
values and risk of death in the overall series was found (w
2=10.3;
P=0.0013) using the ratio between tumour/stromal COX-2 IDV
as continuous covariate (Figure 3).
In multivariate analysis the positivity of tumour COX-2 retained
an independent negative prognostic role for OS (P=0.0004), while
the positivity of stromal COX-2 showed a trend toward a favour-
able role (P=0.056). Similar results were obtained when using
tumour COX-2 and stromal COX-2 as continuous variables (data
not shown).
As shown in Table 2 the status of tumour/stroma COX-2 IDV
ratio together with advanced stage of disease, retained an indepen-
dent negative prognostic role for OS (Table 2). Similar results were
obtained in multivariate analysis considering the values of tumour/
stroma COX-2 IDV ratio as continuous variable in the whole series
as well as in LACC patients (data not shown). Finally, in order to
evaluate the weight of the status of tumour COX-2 and tumour/
stroma COX-2 IDV ratio in the survival regression model, we
tested the signiﬁcance of excluding either the co-variate tumour
COX-2 positivity or tumour/stroma COX-2 IDV positivity from
the model. Indeed, only the tumour/stroma COX-2 IDV gave a
statistically signiﬁcant contribution to the model (likelihood ratio:
w
2 =7.6, P=0.0058)
Moreover, the comparison between the coefﬁcients of relative
risk of death for tumour COX-2 positivity vs tumour/stroma
COX-2 IDV positivity was also analysed in order to test whether
a statistically signiﬁcant difference exists beween the two coefﬁ-
cients. Indeed, in the Cox’s proportional hazard model we found
that the relative risk of death in patients having a tumour/stroma
COX-2 IDV ratio 41 positivity showed a trend to be higher (rela-
tive risk 18.72, 95% CI=1.94–181.0) than that of patients with
tumour COX-2 (relative risk 1.12, 95% CI=0.33–84.0) (Wald
statistics: w
2=3.292; d.f.=1, P=0.069).
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Figure 2 Overall survival rate according to the status of COX-2 in tu-
mour cells (A), in stroma inﬂammatory cells (B), and according to the ratio
between tumour/stroma COX-2 IDV (C) in 99 cervical cancer patients.
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Figure 3 Plot of the estimate of the relative risk of death as a prediction
of COX-2 integrated density values, calculated by COX’s hazard regression
model in cervical cancer patients.
Prognostic role of COX-2 in cervical cancer
G Ferrandina et al
1149
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(10), 1145–1152Immunophenotypic characterisation
Quantiﬁcation of the total amount of cells as well as the expression
of CD3, CD4, CD8, CD25 and tryptase in the stromal inﬂamma-
tory compartment were analysed in nine squamous cervical
cancers randomly chosen among cases with high (41) vs low
(41) tumour/stroma COX-2 IDV ratio. The total amount of cells
observed in the stromal inﬂammatory compartment per unit area
was signiﬁcantly lower in cervical cancer showing high vs low
tumour/stroma COX-2 IDV ratio (mean+s.e.=54.40+6.49 vs
121.67+13.30, P=0.014). Moreover, analysis of the data of CD3,
CD4, CD25, and tryptase immunostaining, represented in Figure
1C–H and summarised in Figure 4, shows that the proportion
of CD3
+, CD4
+, and CD25
+ cells is signiﬁcantly lower in tumours
showing COX-2 positive vs COX-2 negative tumour cells (P=0.014;
0.025, and 0.014, for CD3, CD4, and CD25, respectively). On the
contrary, a higher percentage of tryptase positive mast cells was
detected in stromal inﬂammatory cells from tumours with COX-
2 positive vs COX-2 negative tumour cells (P=0.013). Interestingly,
mast cells endowed with positive tryptase immunostaining were
more frequently observed in tumours showing high versus low
tumour/stroma COX-2 IDV ratio (P=0.014).
Double labelling subtraction consecutive immunostaining of the
same COX-2 positive tumour section by anti-COX-2 and anti-tryp-
tase antibodies showed that the vast majority (470%) of tryptase
positive mast cells also express COX-2 (Figure 5, insert).
DISCUSSION
In this study, we ﬁrst reported that in cervical tumours the expres-
sion of COX-2 in the stroma inﬂammatory cells and its
relationship with COX-2 expression in tumour cells can be clini-
cally relevant. An inverse relationship between COX-2 expression
in tumour cells and the amount of the stroma inﬂammatory inﬁl-
trate in the tumour has been detected.
Moreover, COX-2 positive tumours showed a lower percentage
of COX-2 positive stromal cells/unit area. This ﬁnding seems to
be a distinctive morphologic feature of cervical tumours since we
could not ﬁnd such histopathological pattern in ovarian (Ferrandi-
na et al, 2002a) and endometrial cancer (manuscript submitted),
and suggests that tissue speciﬁc factors may intervene to regulate
tumour/host interactions and characterise the amount and possibly
the composition of stromal cellular inﬁltrate. The association
between the presence of an abundant lymphocytic inﬁltrate in
the stroma and better clinical outcome has been already high-
lighted in cervical cancer (Chao et al, 1999) as well as other
solid tumours (Zeid and Muller, 1993) and associated with the
potentiation of antitumour immune response, although the subpo-
pulations of immune cells involved have been only partially
clariﬁed (Chao et al, 1999; Santin et al, 2001). We showed a lower
percentage of CD3
+, CD4
+ and CD25
+ T cells in tumours with
COX-2 positive immunostaining in tumour cells suggesting that
the expression of high levels of COX-2 in tumour cells can play
a major role in inhibiting host immune functions. In this context,
it is noteworthy that COX-2 can up-regulate the immunosuppres-
sive cytokine IL10, while reducing the production of IL12, which is
critical for cell mediated anti-tumour immunity (Stolina et al,
2000).
We also found a higher number of tryptase positive mast cells in
tumours showing intense vs low COX-2 staining in tumour cells.
Moreover, a large proportion of stromal mast cells was found to
express COX-2, suggesting that they are in an activated state, as
supported by the observations that induction of COX-2 at mRNA
and protein level occurs in antigen-activated mast cells (Hundley et
al, 2001).
Tryptase positive mast cells have been reported to increase from
normal cervical tissue through cervical dysplasias to invasive carci-
noma (Bribiesca-Benitez et al, 2001) and suggested to be involved
in the promotion of tumour angiogenesis through the secretion of
tryptase, a serin-protease able to exert a potent pro-angiogenic
activity in human malignancies (Kankkunen et al, 1997) .
Therefore, the presence of high COX-2 expression in cervical
tumour cells seems to be associated with a scarce cellular inﬁltrate
in the stroma and, notably, with a lower proportion of immunor-
egulatory cells and a high proportion of tryptase positive mast cells.
At present, our data do not allow to indicate the mechanisms and
direction of tumour/host interaction relative to COX-2 expression.
The possible active role of COX-2 expression in the stromal
compartment of the tumour in terms of tumour cell/ stromal cell
cross-talk has been recently highlighted (Prescott, 2000). In parti-
cular, Lehay et al (2002) showed that induction of apoptosis by
COX-2 inhibitors in angiogenic cells is associated with antitumour
activity, suggesting that COX-2 expression in stromal elements
such as the vasculature could play a major role in tumour biology.
This issue is relevant in order to understand the role of COX-2
according to different compartments, and warrants further investi-
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Table 2 Univariate and multivariate analysis of clinico-pathological para-
meters and tumour/stroma COX-2 IDV ratio as prognostic factors in cer-
vical cancer patients
Univariate Multivariate
a
Variable RR1 w
2 P value RR2 w
2 P value
Age (years)
550 1
0
550 1.4 0.6 0.43 – – –
Stage
I–II 1
0 1
0
III–IV 6.6 15.8 0.0001 3.5 6.2 0.012
Histotype
Squamous 1
0 1
0
Other 3.2 6.1 0.013 2.1 2.1 0.14
Tumour size
54c m 1
0 1
0
54 cm 13.8 6.6 0.010 5.5 2.6 0.1
Grade
G1–2 1
0 1
0
G3 0.5 2.1 0.14 0.7 0.4 0.5
Tumour/stroma COX-2 IDV ratio
Low 1
0 1
0
High 21.5 8.9 0.0020 11.4 5.3 0.020
aOnly variables with P value50.30 in the univariate analysis were included in the
multivariate model. RR1=unadjusted relative risk. RR2=relative risk after adjusting
for all the factors listed. 1
0=reference category.
%
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CD3+        CD4+        CD8+         CD25+    Tryptase+
*
* *
*
Figure 4 Percentage of CD3
+, CD4
+, CD8
+, CD25
+, and tryptase po-
sitive cells in stroma inﬂammatory inﬁltrate of cervical tumours from cases
with low (gray columns) vs high (black columns) tumour/stroma COX-2
IDV ratio (results are expressed as mean+s.e.; *signiﬁcant at P50.05).
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subtypes (lymphocytes, endothelial cells, macrophages, etc) in
tumour stroma.
From a clinical point of view, it is noteworthy that, while COX-
2 in tumour cells identiﬁes cervical cancer patients with unfavour-
able prognosis, COX-2 expression in stroma inﬂammatory
compartment is associated with better clinical outcome, suggesting
that COX-2 positive stromal cells can play a role in reducing
tumour cell aggressiveness. Therefore, the balance between COX-
2 expression in the tumour and in the stroma area, rather than
the independent evaluation of each compartment, could offer addi-
tional prognostic information. In this context, the use of the ratio
between COX-2 in the tumour cells and COX-2 in the stroma cells,
seems to be a more effective estimate of the cross-talk occurring
between tumour tissue and its stromal compartment (Prescott,
2000; Williams et al, 2000). This ratio represents a valuable tool
to normalise the amount of COX-2 expression in the tumour on
the basis of the status of its stromal component, and to minimize
the bias inherent to the use of an arbitrary cut-off.
Indeed, we showed that the ratio between COX-2 in the tumour
cells and COX-2 in the stroma cells was very effective in distin-
guishing patients with low vs high risk of death of disease both
in univariate and multivariate analysis. Finally, a very strong corre-
lation between both tumour COX-2 expression and tumour/stroma
COX-2 IDV ratio were shown to be highly correlated with response
to chemotherapy while, although high COX-2 expression in the
stroma was signiﬁcantly associated with better survival, it failed
to directly correlate with response to treatment.
In conclusion, our study showed the usefulness of assessing
COX-2 status both in tumour and stroma compartment in order
to identify cervical cancer patients endowed with a very poor
chance of response to neoadjuvant therapy and unfavourable prog-
nosis. This group of patients could possibly beneﬁt of more
individualised treatments, such as selective COX-2 inhibitors,
which are already approved for treatment of familial colorectal
adenomatous polyposis, and started to be explored in Phase I–II
studies (Snyderman, 2001).
ACKNOWLEDGEMENTS
This work was ﬁnancially supported by grants from Ministero
dell’Universita ` e della Ricerca Scientiﬁca e Tecnologica (MURST)
and Italian Association for Cancer Research (AIRC)
REFERENCES
Benedetti-Panici P, Maneschi F, Cutillo G, Greggi S, Salerno MG, Amoroso
M, Scambia G, Mancuso S (1996) Modiﬁed type IV-V radical hysterect-
omy with systematic pelvic and aortic lymphadenectomy in the
treatment of patients with stage III cervical carcinoma. Feasibility, techni-
que and clinical results. Cancer 78: 2359–2365
Bribiesca-Benitez L, Wong A, Utrera D, Castellanos E (2001) The role of mast
cell tryptase in neoangiogenesis of premalignant and malignant lesions of
the uterine cervix. J Histochem Cytochem 49: 1061–1062
Chao HT, Wang PH, Tseng JY, Lai CR, Chiang SC, Yuan CC (1999) Lympho-
cyte-inﬁltrated FIGO Stage IIB squamous cell carcinoma of the cervix is a
prominent factor for disease-free survival. Eur J Gynecol Oncol 2: 136–140
Cox DR (1970) Analysis of binary data. London: Methven
Cox DR (1972) Regression models and life tables. J Royal Statist Soc 34: 197–
220
Ferrandina G, Lauriola L, Zannoni GF, Fagotti A, Fanfani F, Legge F, Maggia-
no N, Gessi M, Mancuso S, Ranelletti FO, Scambia G (2002a) Increased
cyclooxygenase-2 (COX-2) expression is associated with chemotherapy
resistance and outcome in ovarian cancer patient. Ann Oncol 13: 1205–
1211
Ferrandina G, Lauriola L, Distefano MG, Zannoni GF, Gessi M, Legge F,
Maggiano N, Mancuso S, Capelli A, Scambia G, Ranelletti FO (2002b)
Increased cyclooxygenase-2 (COX-2) expression is associated with
chemotherapy resistance and poor survival in cervical cancer patients. J
Clin Oncol 20: 973–981
Gaffney DK, Holden J, Zempolichi K, Murphy KJ, Dicker AP, Dodson M
(2001) Elevated cyclooxygenase-2 expression in cervical carcinoma.
Reduced cause-speciﬁc survival and pelvic control. Am J Clin Oncol 24:
413–416
Hundley TR, Prasad AR, Beaven MA (2001) Elevated levels of Cyclooxygen-
ase-2 in antigen-stimulated mast cells is associated with minimal activation
of p38 mitogen-activated protein kinase. J Immunol 167: 1629–1636
Iniguez MA, Punzon C, Fresno M (1999) Induction of cyclooxygenase-2 on
activated T lymphocytes: regulation of T cell activation by cyclooxygenase
inhibitors. J Immunol 163: 111–119
Kankkunen J, Harvima I, Naukkariner A (1997) Quantitative analysis of tryp-
tase and chymase containing mast cells in benign and malignant breast
lesions. Int J Cancer 72: 385–388
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Figure 5 Tryptase staining in mast cells. Double labelling subtraction consecutive immunostaining of the same COX-2 positive tumour section by anti-
COX-2 and anti-tryptase antibodies showed that the vast majority (470%) of tryptase positive mast cells also express COX-2 Figure 6., insert). Bar: 50 mm.
Prognostic role of COX-2 in cervical cancer
G Ferrandina et al
1151
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(10), 1145–1152Kaplan E, Meyer P (1958) Non parametric estimation from incomplete
observations. J Am Statist Assoc 53: 457–481
Lehay KM, Ornberg RL, Wang Y, Zwifel BS, Koki AT, Masferrer JL (2002)
Cyclooxygenase 2 inhibition by Celecoxib reduces proliferation and
induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 62:
625–631
Mantel N (1966) Evaluation of survival data and two new rank order statistics
arising in its consideration. Cancer Chemother Rep 50: 163–170
Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM,
Edwards DA, Flickinger AG, Moore RJ, Seibert K (2000) Antiangiogenic
and antitumour activities of cyclooxygenase-2 inhibitors. Cancer Res 60:
1306–1311
Prescott SM (2000) Is cyclooxygenase-2 the alpha and the omega in cancer?
Clin Invest 105: 1511–1513
Ranelletti FO, Almadori G, Rocca B, Ferrandina G, Ciabattoni G, Habib A,
Galli J, Maggiano N, Gessi M, Lauriola L (2001) Prognostic signiﬁcance
of cyclooxygenase-2 expression in laryngeal squamous cell carcinoma.
Int J Cancer 95: 343–349
Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu
H, Isola J (2002) Prognostic signiﬁcance of elevated cyclooxygenase-2
expression in breast cancer. Cancer Res 62: 632–635
Santin AD, Ravaggi A, Bellone S, Pecorelli S, Cannon M, Parham GP,
Hermonat PC (2001) Tumour-inﬁltrating lymphocytes contain higher
numbers of type 1 cytokine expressors and DR+ T cells compared with
lymphocytes from tumour draining lymph nodes and peripheral blood
in patients with cancer of the uterine cervix. Gynecol Oncol 81: 424–432
Snyderman M (2001) Biologically useful responses of human neoplasia to
Celecoxib and Lovastatin. Proceedings of the American Society of Clinical
Oncology (abstract) San Francisco, May 2001
Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, Zhu L,
Kronemberg M, Miller PW, Portanova J, Lee JC, Dubinett SM (2000)
Speciﬁc inhibition of cyclooxygenase-2 restores antitumour reactivity by
altering the balance of IL-10 and IL-12 synthesis. J Immunol 164: 361–370
Tomozawa S, Tsuno NH, Sunami E, Hatano K, Kitayama S, Osada T, Saito S,
Tsuruo T, Shibata Y, Nagawa H (2000) Cyclooxygenase-2 overexpression
correlates with tumour recurrence, especially haematogenous metastasis
of colorectal cancer. Br J Cancer 83: 324–328
Tsujii M, DuBois RN (1995) Alterations in cellular adhesion and apoptosis in
epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell
83: 493–501
Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998)
Cyclooxygenase-2 regulates angiogenesis induced by colon cancer cells.
Cell 93: 705–716
Williams CS, DuBois RN (1996) Prostaglandins endoperoxide synthase: why
two isoforms? Am J Physiol 270: 393–400
Williams CS, Tsujii M, Dey SK, DuBois RN (2000) Host cyclooxygenase-2
modulates carcinoma growth. J Clin Invest 105: 1589–1594
World Health Organization (1979) WHO handbook for reporting results of
cancer treatment. WHO, Geneva 1979 Offset publication no. 48 16–21
Yamada T, Sawatsubashi M, Yakushji H, Itoh Y, Edakuni G, Mori M, Robert
L, Miyazaki K (1998) Localization of vascular endothelial growth factor in
synovial membrane mast cells: examination with ‘multi-labelling subtrac-
tion immunostaining’. Virchows Arch 433: 567–570
Zeid NA, Muller HK (1993) S100 Positive dendritic cells in human lung
tumors associated with cell differentiation and enhanced survival. Pathol-
ogy 25: 338–343
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Prognostic role of COX-2 in cervical cancer
G Ferrandina et al
1152
British Journal of Cancer (2002) 87(10), 1145–1152 ã 2002 Cancer Research UK